Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NEKTAR THERAPEUTICS

(165417)
  Bericht
Verzögert Nasdaq  -  22:00:01 03.02.2023
3.090 USD   +3.00%
11.01.Transcript : Nektar Therapeutics Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 08:15 AM
CI
2022Transcript : Nektar Therapeutics - Shareholder/Analyst Call
CI
2022Nektar und Mitarbeiter geben Veröffentlichung von präklinischen Daten in Blood Advances bekannt, die zeigen, dass NKTR-255, ein neuartiges Polymer-konjugiertes menschliches IL-15, die Wirksamkeit einer CD19-gerichteten CAR-T-Zell-Immuntherapie verbessert
CI
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über NEKTAR THERAPEUTICS
09.01.Nektar Therapeutics : Results of Operations and Financial Condition, Regulation FD Disclos..
05.01.Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P..
04.01.Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P..
2022Nektar Therapeutics : Other Events (form 8-K)
2022Nektar Therapeutics : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fin..
2022Nektar Therapeutics to Host Investor & Analyst Event on December 12th
2022Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Pro..
2022Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Dem..
2022NEKTAR THERAPEUTICS Management's Discussion and Analysis of Financial Condition and Re..
2022Nektar : Q3 Earnings Snapshot
2022Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q3 Revenue $23.6M
2022Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q3 Revenue $23.6M, vs. Street Est of ..
2022Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ende..
2022Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3..
2022Nektar Therapeutics : NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, I..
2022Nektar Therapeutics : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
2022Pound Could Fall Further as BOE's Gilt Intervention Ends Soon
2022BOE's Decision to Buy Index-Linked Gilts Could Reduce Aggressive Selling
2022FTSE 100 Falls as Jobs Data Fuel BOE Rate Rise Bets
2022Longer Period of Support for Gilts Could Be Necessary, Says ING
2022EN DIRECTO DESDE LOS MERCADOS: Telefónica, BBVA, Airbus, ..
2022FTSE 100 Seen Lower Again as Risk Aversion Continues
2022Qui capitulera en premier ?
2022EN DIRECT DES MARCHES : Airbus, BNP Paribas, Sanofi, EDF, TSMC, Gi..
2022PureTech Health Terminates Merger Discussions With Nektar Therapeutics
2022Nektar Therapeutics cancelled the acquisition of PureTech Health plc.
2022Form 8 (OPD) Nektar Therapeutics, Inc.
2022FTSE Closed Lower Despite Positive US Jobs Data
2022PureTech Health, Nektar Therapeutics Shares Decline After Confirming Merger Talks
2022Wall Street Set to Open Lower as Jobs Report Shows Tight Labor Market
2022US Futures Mixed Ahead of September Jobs Report
2022Top Premarket Decliners
2022Nektar Therapeutics : Statement regarding recent press speculation - Form 8-K
2022Nektar Therapeutics : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
2022FTSE 100 Struggles in Cautious Trade Before U.S. Jobs Data
2022Sterling Unlikely to Stay Above $1.10 For Long, ING Says
2022Outlook for Gilts Remains Bearish, Says Citi
2022London Stocks Seen Lower; Investors on Edge Ahead of US Jobs Data
2022PureTech Health Confirms Merger Negotiations with Nektar Therapeutics
2022Nektar Therapeutics submitted a non-binding proposal to acquire PureTech Health plc.
2022Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with At..
2022Nektar Therapeutics Presents Data for Rezpegaldesleukin in Patients with Atopic Dermati..
2022Insider Sell: Nektar Therapeutics
2022Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Obse..
2022North American Morning Briefing: Stocks to -2-
2022NEKTAR THERAPEUTICS Management's Discussion and Analysis of Financial Condition and Re..
2022Nektar : Q2 Earnings Snapshot
2022Nektar Therapeutics : Reports Second Quarter 2022 Financial Results - Form 8-K
2022Nektar Therapeutics Provides Earnings Guidance for the Year 2022
2022Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q2 Revenue $21.6M
2022Nektar Therapeutics Reports Second Quarter 2022 Financial Results
2022Nektar Therapeutics Reports Earnings Results for the Second Quarter and Six Months Ende..
2022Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4,..
2022BB Biotech: in 2* trim perdita di 233 mln chf (+129 mln in 2021)
2022Nektar Therapeutics : Change in Directors or Principal Officers (form 8-K)
2022Nektar Therapeutics Promotes Jillian Thomsen to CFO
2022Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Finan..
2022Nektar Promotes Jillian B. Thomsen to Chief Financial Officer
2022Nektar Promotes Jillian B. Thomsen to Senior Vice President
2022Nektar Therapeutics(NasdaqGS:NKTR) added to Russell 2000 Va..
2022Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 100..
2022Nektar Therapeutics(NasdaqGS:NKTR) added to Russell 2000 In..
2022Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 100..
2022Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell Mid..
2022Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 100..
2022Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell Mid..
2022Nektar Therapeutics(NasdaqGS:NKTR) added to Russell 2000 Dy..
2022Nektar Therapeutics : Submission of Matters to a Vote of Security Holders (form 8-K)
2022Nektar Therapeutics : 2022 Annual Shareholder Meeting Presentation
2022Nektar Therapeutics : Other Events (form 8-K)
2022Nektar Therapeutics Reviews Interim Efficacy and Safety Data from the Ongoing Phase 2 D..
2022This Week At The Ninth : Cancer Drugs And COVID Grants
2022NEKTAR THERAPEUTICS Management's Discussion and Analysis of Financial Condition and Re..
2022Nektar : Q1 Earnings Snapshot
2022Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q1 Revenue $24.8M
2022Nektar Therapeutics Reports Earnings Results for the First Quarter Ended March 31, 2022
2022Nektar Therapeutics Reports First Quarter 2022 Financial Results
2022Nektar Therapeutics : Costs Associated with Exit or Disposal Activities, Material Impairme..
2022Nektar to cut over 500 jobs following cancer drug failure
2022Nektar Therapeutics Plans to Focus Resources on Key Research; Cuts 70% of Workforce; Ex..
2022Nektar Therapeutics : Announces Strategic Reorganization Plan and Corporate Outlook - Form..
2022Nektar Therapeutics : Results of Operations and Financial Condition, Change in Directors o..
2022John Northcott Step Down as Senior Vice President and Chief Commercial Officer of Nekta..
2022Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor A..
2022Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline..
2022Correction: Sector Update: Health Care Stocks Stumble Monday Afternoon
2022Sector Update: Health Care Stocks Stumble Monday Afternoon
2022Sector Update: Health Care Stocks Retreating to Begin New Week
2022Nektar Therapeutics Plunges After Joint Trials With Bristol-Myers Squibb Stopped for Ca..
2022Top Midday Decliners
2022Sector Update: Health Care Stocks Modestly Lower Pre-Bell Monday
2022Wall Street Set for Narrow Losses Amid Rising Bond Yields
2022Top Premarket Decliners
2022Nektar Therapeutics, Bristol-Myers Squibb Stop Trials of Cancer Combination Therapy
2022Nektar stops clinical trials for key cancer drug, shares tumble
2022Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program
2022Nektar Therapeutics : and Bristol Myers Squibb Announce Update on Clinical Development Pro..
2022Nektar Therapeutics : Other Events, Financial Statements and Exhibits (form 8-K)
2022Nektar, Bristol Myers end clinical trial program for cancer drug combo
2022Nektar Therapeutics and Bristol-Myers Squibb Company Announce Update on Clinical Develo..
Anstehende Termine für NEKTAR THERAPEUTICS